ADC Therapeutics Announces the Results of Zynlonta in the P-II Trial for the Treatment of Follicular Lymphoma
Shots:
- The P-II study evaluating Zynlonta (loncastuximab-tesirine-lpyl) + rituximab in patients (aged 47 to 89yrs) with r/r FL who are treated with ≥1 line of systemic therapy & meet GELF criteria or POD24 at baseline
- The 1EP of the study includes a complete response (CR) by week 12 on PET/CT. The result of the study depicted an ORR of 96.3% & CR rate of 85.2% along with a PFS of 92.3% with a median follow-up of 12mos. Additionally, the median PFAS was not met
- Zynlonta functions as ADC that targets CD19. When it binds to a cell expressing CD19, the cell internalizes it, & enzymes subsequently release a drug payload containing pyrrolobenzodiazepines (PBD)
Ref: ADC Therapeutics | Image: ADC Therapeutics
Related News:- Overland ADCT BioPharma Reports the NMPA Acceptance of BLA and Granted Priority Review for Zynlonta for Diffuse Large B-cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
